Literature DB >> 26434091

Use of Screening Tests for Colorectal Cancer Among Gynecologists in Puerto Rico.

J Romaguera, S Seymour, V Cabrera, J Medina, E De Jesus, A P Ortiz.   

Abstract

OBJECTIVE: To determine the use of screening tests for colorectal cancer (CRC) among Gynecologists in Puerto Rico. This study evaluates the screening practices used by Gynecologists in PR to diagnose CRC and adherence to screening guidelines.
METHODS: A self-administered anonymous questionnaire was mailed to 440 practicing gynecologists through the College of Physicians and Surgeons of PR. The questionnaire included general and specific questions.
RESULTS: Response rate was 23.2% (102/440). Of this group of gynecologists, 77.5% referred screening patients, while 22.5% did not. The majority (28.4%) use Fecal Occult Blood Test (FOBT) as a first screening test, while 27.5% use Colonoscopy. Screening is started by 49% at age 50. Only 7% stop screening at 75 years and 31% never stop screening. CRC Screening performed by participants were: 35% screen annually, 6% screen 2-3 years, 10% screen every 5 years, 6% screen every 10 years and 6% screen 5-10 years. Data for CRC Screening reveals 7% gynecologists comply with all the guidelines; 49% comply with the recommendations regarding the start screening age and 7% stop screening as per guidelines.
CONCLUSION: The recommendations are not followed by most of the gynecologists in PR that participated in the study, Further research should be directed towards the reasons for not complying and how to educatethemedical population to achieve adequate screening in the PR female population.

Entities:  

Mesh:

Year:  2015        PMID: 26434091

Source DB:  PubMed          Journal:  Bol Asoc Med P R        ISSN: 0004-4849


  1 in total

1.  Cancer in populations of African Ancestry: studies of the African Caribbean Cancer Consortium.

Authors:  Camille Ragin; Elizabeth Blackman; Robin Roberts; Raleigh Butler; Samuel Gathere; Darron Halliday; Kimlin Ashing
Journal:  Cancer Causes Control       Date:  2017-11       Impact factor: 2.506

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.